Spontaneous Uterine Rupture in a Multigravid Pregnant Woman with Unscarred Uterus on Chronic Steroid Use: A Case Report.

CONCLUSION: Uterine rupture may be associated with chronic use of corticosteroids. Identifying the different risk factors for uterine rupture can lead to more prompt diagnosis and management of uterine rupture, resulting in better maternal and fetal outcomes. PMID: 32690461 [PubMed - as supplied by publisher]
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Related Links:

Pregnancy outcomes data are increasingly emerging but dermatologists, rheumatologists, and their female patients with psoriasis and psoriatic arthritis (PsA) want much more.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Ob/Gyn & Women ' s Health News Source Type: news
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have be...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion ava...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Authors: Esposito M, Carubbi F, Giunta A, Alunno A, Giacomelli R, Fargnoli MC Abstract Introduction: Certolizumab pegol (CZP) is a Fc-free PEGylated TNF-α inhibitor approved for the treatment of psoriatic arthritis (PsA) and plaque psoriasis in many countries. It demonstrated favorable results in PsA in terms of improvement in peripheral arthritis, dactylitis and enthesitis in a phase III trial (RAPID-PSA) and in real-life experiences. Recently, 3 phase III randomized clinical trials (CIMPASI-1, CIMPASI-2, CIMPACT) showed significant, clinically meaningful, and sustained improvements in signs and symptoms of ...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Introduction: Psoriasis (PSO) and psoriatic arthritis (PsA) often affect women of childbearing age; but it is unclear if these women ( ♀) feel able to make informed treatment decisions around pregnancy and breastfeeding. This survey gained insight on disease management and pregnancy, to assess if they feel adequately supported. Methods: Women (18–45 years) with chronic inflammatory diseases from the US, Japan, and Germany, Fran ce, UK, Italy and Spain (EU5) participated in a 20-min online survey (Jul–Oct 2017; InSites Consulting).
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Introduction: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases (rheumatoid arthritis/axial spondyloarthritis/psoriatic arthritis/Crohn's disease). Adequate disease control is crucial to reduce the risk of adverse pregnancy outcomes. Anti-TNFs are effective therapies, but because most cross the placenta they are often stopped during pregnancy. Certolizumab pegol (CZP), due to its Fc-free molecular structure, is not expected to undergo placental transfer compared to other anti-TNFs.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Basic Science 6 – Teratology genetics and outcomes Source Type: research
(MedPage Today) -- No adverse effect on birth outcomes, and many reported fewer joint symptoms during pregnancy
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news
ConclusionsPsA patients do not have more infertility or worse pregnancy outcomes compared to healthy controls.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Arthritis | Canada Health | Corticosteroid Therapy | OBGYN | Pregnancy | Psoriatic Arthritis | Rheumatology | Study